

Track record – Diseases – Metabolic diseases

Treatment-dependent and treatment-independent risk factors associated with the risk of diabetes-related events: a retrospective analysis based on 229,042 patients with type 2 diabetes mellitus. Wilke T, Mueller S, Groth A, Fuchs A, Seitz L, Kienhöfer J, Maywald U, Lundershausen R, Wehling M. *Cardiovasc Diabetol.* 2015 Feb 3;14:14. doi: 10.1186/s12933-015-0179-2.

Cost-effectiveness of statins for primary prevention in patients newly diagnosed with type 2 diabetes in the Netherlands. de Vries FM, Denig P, Visser ST, Hak E, Postma MJ. *Value Health.* 2014 Mar;17(2):223-30. doi: 10.1016/j.jval.2013.12.010.

Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review. Huang Y, Zhou Q, Haaijer-Ruskamp FM, Postma MJ. *BMC Nephrol.* 2014 Jan 15;15:15. doi: 10.1186/1471-2369-15-15. Review.

Real life treatment of diabetes mellitus type 2 patients: An analysis based on a large sample of 394,828 German patients. Wilke T, Groth A, Fuchs A, Seitz L, Kienhöfer J, Lundershausen R, Maywald U. *Diabetes Res Clin Pract.* 2014;Epub ahead of print.

Non-Adherence And Non-Persistence Related To Glp-1 Therapy In Patients With Diabetes Mellitus Type 2 (T2dm): Analysis of A Large German Claims-Based Dataset And Comparison To Oral Anti-Diabetics. Wilke T, Groth A, Berg B, Sikirica M, Martin AA, Fuchs A, Maywald U. *Value in Health.* 2014;17(7):A359.

How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus. Wilke T, Groth A, Müller S, Reese D, Linder R, Ahrens S, Verheyen F. *Eur J Health Econ.* 2013;14(3):551-568.

Incidence and prevalence of type 2 diabetes mellitus in Germany: an analysis based on 5.43 million patients. Wilke T, Ahrendt P, Schwartz D, Linder R, Ahrens S, Verheyen F *Dtsch Med Wochenschr.* 2013;138(3):69-75.

Prevalence and Incidence of Type 2 Diabetes Mellitus: An Analysis Based on 5.4 Million Patients. Wilke T, Groth A, Müller S, Ahrendt P, Schwartz D, Linder R, Ahrens S, Verheyen F. *Value in Health.* 2012;15(4):A174-A175.

Oral anticoagulation used by patients with atrial fibrillation in Germany. Adherence to guidelines, causes of anticoagulation under-use and its clinical outcomes, based on claims-data of 183,448 patients. Wilke T, Groth A, Müller S, Pfannkuche M, Verheyen F, Linder R, Maywald U, Kohlmann T, Feng YS, Breithardt G, Bauersachs R. *Thrombosis & Haemostasis.* 2012;107(6):1009–1194.

A novel approach for non-adherence measurement based on prescription data: the example of oral diabetics in the therapy of type-2 diabetes mellitus patients. Wilke T, Mueller S, Lindner R, Ahrens S, Verheyen F. *Value in Health.* 2011;14:A99.

Anforderungen an ein effektives Adherence-Persistence-Programm am Beispiel von oralen Antidiabetika bei Diabetes mellitus Typ 2-Patienten. Wilke T, Müller S, Groth A, Maywald U, Verheyen F. *Gesundheitsökonomie & Qualitätsmanagement.* 2011;16(5): 274-291.

The methodological quality and effectiveness of adherence interventions: a review of diabetes type II interventions. *Value in Health.* Wilke T, Müller S, Groth A 2010;13(7):A295–A296.

The economic benefits of preventing end-stage renal disease in patients with type 2 diabetes mellitus. Postma MJ, de Zeeuw D. *Nephrol Dial Transplant.* 2009 Oct;24(10):2975-83. doi: 10.1093/ndt/gfp352. Epub 2009 Jul 15. Review. No abstract available.

Pharmacoeconomics of angiotensin II antagonists in type 2 diabetic patients with nephropathy: implications for decision making. Boersma C, Athobari J, Gansevoort RT, de Jong-Van den Berg LT, de Jong PE, de Zeeuw D, Annemans LJ, Postma MJ. *Pharmacoeconomics.* 2006;24(6):523-35. Review.